AUTHOR INDEX

Abraham G, 73, 203, 349, 355
Abreu-Gonzalez P, 349
Ahlmén J, 79
Alexiou P, 57
Allouache M, 289
Alon U, 81
Andrews M, 351
Arisz L, 15

Baick SH, 75
Bailie GR, 356
Bakkeren JAJM, 261
Balaskas E, 57
Balfe JW, 277
Balteau P, 165
Bargman J, 73, 241
Barrientos A, 121
Barzaghi V, 165
Baumelou A, 289
Belpaire FM, 95
Bennett-Jones DN, 333
Benz RL, 222, 285
Bernardini J, 127
Blake P, 73, 349, 355
Boelaert JR, 95
Bogaert MG, 95
Boletis I, 65
Bos HJ, 179
Breborowicz A, 85, 135
Briggs JD, 115
Brock JH, 115
Brown CB, 65
Brown WW, 27
Buchwald R, 295
Buoncristiani U, 149

Calmon J, 222
Cameron JS, 61, 333
Campbell A, 351
Canadian CAPD Clinical Trials Group, 159
Cantaluppi A, 165, 169
Caridad A, 353
Carlsson L, 79
Caruana RJ, 319
Castelnovo C, 37, 207
Caterson RJ, 107
Cavalli PL, 165
Chakrabarti E, 211
Chan H, 203
Chazan JA, 143
Cheek PL, 319
Chiba T, 221
Churchill DN, 51
Cichocki T, 313
Cigarran S, 329
Clark DD, 143
Cocksedge B, 107
Cohen GL, 65
Coles GA, 69
Colombo A, 165, 321
Colomer B, 353
Conte G, 273
Coronel F, 121
Czyżewska K, 303

Daelemans R, 111
Daneels RF, 95
David T, 355
Davies M, 69
Davies SJ, 61
de Baz H, 145
De Broe ME, 111
De Cre MJ, 95
De Cristofaro V, 37
De Vecchi A, 37, 165, 207
Deray G, 289
Dessau RB, 351
Di Paolo B, 211
Di Paolo N, 41, 151
Diaz-Buxo JA, 9
Dobbie JW, 215, 341
Dombros N, 57
Donnelly PK, 307
Durivage MF, 356

Edebo L, 79
Edwards R, 103
El Nahas AM, 65
Eriksson C, 79
Escuin F, 329
Essers L, 267
Everett ED, 239, 247

Farrell PC, 29, 107
Feehally J, 351
Ferguson IA, 47
Fifield R, 69
Filik R, 103
Finch RG, 103
Fine A, 99
Fine RN, 91, 239, 247
Fine SE, 91
Foulks CJ, 223
Franceschin A, 145
Frifelt JJ, 351
Fuiano G, 273

Gandolfo C, 165
Garcia-Nieto V, 349
Gilgore GS, 285
Gillespie CME, 333
Gokal R, 239, 247
Golinska BT, 341
Golper TA, 239, 247
Grabensee B, 267
Grahame GR, 47
Grzegorzewska A, 303
Guerra L, 165, 207

Haberstroh B, 73
Hallett MD, 107
Hanicki Z, 313
Heaf JG, 281
Heezius ECJM, 179
Heimbürger O, 179
Hellerstein S, 81
Hess CP, 319
Hidai H, 221
Hjelle JT, 341
Holley JL, 223
Hortal L, 121
Horton JK, 69
Hwang SD, 75

Ibels LS, 29, 107
Imbasciati E, 37
Issad B, 289

Jacobs C, 289
Joffe P, 281
Johnson BF, 65
Johnson CA, 225, 241
Johnston JR, 127
Jones BF, 352
Junor BJR, 115

Kant KS, 355
Kapsner CO, 235
Keane WF, 239, 247
Keller E, 267
Keshaviah PR, 257

Khanna R, 131
Knapowski J, 135, 303
Kooh SW, 277
Korzets A, 351
Krediet RT, 15
Kriley M, 81
Kuhlmann U, 191
Kuyken Ch, 111

L-Revuelta K, 329
Lake N, 352
Ledermann SE, 277
Lee HB, 75
Lee J, 75
Lee MS, 75
Lees P, 175
Lenthe SS, 357
Lesar TS, 356
Lindholm B, 179
Lins RL, 111
Lloyd JK, 215
Luzar MA, 169
Lysaght MJ, 29

Machleidt C, 191
Mactier, 155
Madden AM, 307
Maher JF, 211
Mahony JF, 107
Manuel MA, 51
Martis L, 325
Mathews R, 73
Matthys EG, 95
Matzke GR, 239, 247
McAlack R, 222
McCarroll DR, 341
McGregor SJ, 115
Mettang T, 191
Miguel A, 353
Miguel JL, 329
Minors SJ, 69
Monnens LAH, 261
Moore HL, 131
Moorhead PJ, 65
Moran JE, 29
Moss AH, 223
Muñoz J, 329

Nani E, 273
Naranjo P, 121
Ngu JL, 357
Nicholson ML, 307
Nikolaidis P, 57
Noble WC, 61
Nolph KD, 131, 145, 257, 325

Oe PL, 197
Ogg CS, 61, 333
Ojo B, 51
Olsen OB, 351
Oreopoulos DG, 1, 73, 85, 135, 203

Pagliari B, 37
Park MS, 75
Passlick J, 267
Paton TW, 51
Peluso F, 165
Peluso FP, 169
Pena JC, 295
Perez JC, 319
Peterson PK, 239, 247
Piraino B, 127, 225
Pollock CA, 29, 107
Pomer S, 82
Ponticelli C, 37
Port FK, 309
Poston S, 61
Poupard J, 222
Pozo C, 121
Prats D, 121
Prentice M, 351
Price JDE, 363

Raftery AT, 65
Rambausek M, 82
Ramon G, 353
Ramos P, 329
Rasmussen RT, 356
Rau J, 82
Rayner A, 356
Renzetti G, 165
Reynolds J, 175
Ritz E, 82
Rocher L, 175
Rodela H, 85, 135
Rottembourg J, 289

Sacchi G, 41
Scalamogna A, 37, 165, 207
Schinella D, 145
Schleifer CR, 222, 285
Schröder CH, 261
Schurgers ML, 95
Seibert DG, 223
Selgas R, 329
Sepe V, 273
Serkes KD, 325
Shemin D, 143
Sherman BM, 91
Sigler MH, 285
Skott H, 351
Slingeneyer A, 169
Smith KL, 319
Sorkin MI, 127
Staerz E, 191
Steidley KR, 341
Steiner RW, 5
Sułowicz W, 313
Suresh KR, 309
Swartz R, 175

Takatsu S, 221
Teehan BP, 285
Torchia M, 47
Torgersen AK, 79
Torrente J, 121
Torres-Ramirez A, 349
Tourkantonis A, 57
Tranæus A, 179
Twardowski ZJ, 131
Tzamaloukas AH, 143, 235

van Bronswijk H, 197
van der Meulen J, 197
Van Stone JC, 257
Vandepitte K, 111
Vas M, 349
Vas S, 73, 239, 247, 349
Veitch PS, 307
Verbrugh HA, 179
Verhoef J, 197
Vieth R, 277
Viglino G, 165
Viscione M, 273

Walker SE, 51
Walls J, 351
Warady B, 81
Waters DC, 341
Weber J, 191
Weemaes CMR, 261
Wegmann W, 321
Weinreich Th, 82
Wilcox MH, 103
Williams AJ, 65
Winchester JT, 363
Wonner R, 267
Wright N, 51

Yewdall VMA, 333
Youmbissi TJ, 357

Zachée P, 111
Zeier M, 82
Ziegler C, 47
Zimmerman SW, 225, 241

SUBJECT INDEX

Abdominal hernia, 307
Acid phosphatase, 313
Acid tolerance, 197
Adequacy, 257
Adherence, 103
Alcohol, 211
Amyloidosis, 29, 37
Anemia, 95
Anthropometric measurements, 295
Antibiotics, 103
Antimicrobial activity, 115
Antimicrobial agents, 267
Aztreonam, 57, 273

Basement membrane, 41
Beta-2 amyloidosis, 321
Beta-2 microglobulin, 29, 37
Beta-glucuronidase, 313
Bioavailability, 51
Blood viscosity, 131
Bone complications, 37
Bowel perforation, 307
Bupivacaine, 135

CAPD fluids, 197
Calcitriol administration, 277
Calcium, 325
Calcium carbonate, 325
Catheter infections, 127
Catheter loss, 61
Catheter replacement, 65
Cefazolin, 191
Cefuroxime, 273
Chemiluminescence, 333
Childhood CAPD, 257
Clearances, 131
Coagulase-negative staphylococci, 103
Complement, 69, 333
Complications, 179, 319
Connection systems, 165
Continuous ambulatory intraperitoneal calcium therapy, 285
Continuous ambulatory peritoneal dialysis (CAPD), 51
Cytokeratin, 341
Cytotoxicity in vitro, 197

1,25-dihydroxyvitamin D, 277
D-lactate metabolism, 99
Diabetes mellitus, 121
Diabetic nephropathy, 289
Diagnosis, 179
Disconnect systems, 169, 175
Disinfectant, 169
Duration of therapy, 191

End-stage renal disease, 289
Erythropoietin, 95
Exit site, 127
Exit-site infection, 61, 127

Fluconazole, 79
Flush, 169
Fungal peritonitis, 79

Gentamicin, 191
Glucose absorption, 211
Glucose-6-phosphatase deficiency, 111
Glycogen storage disease, 111
Growth, 91

Hemodialysis, 29, 37, 257
Hungry bone syndrome, 285
Hyperparathyroidism, secondary, 285
Hyperphosphatemia, 325
Hypocalcemia, 285
Hypoglycemia, 111

IgG_2 deficiency, 257
IgG, 333
Immunoglobulin, 69
Intraabdominal air, 307
Intraperitoneal instillation, 91
Intraperitoneal insulin, 289

KoA, 29

L-lactate metabolism, 99
Lamellar bodies, 215
Long-term CAPD, 321
Long-term dialysis, 329
Lymphatic reabsorption, 107
Lymphatics, 85

Mass transfer area coefficient, 329
Mass transfer, 281
Mass transport, 29
Mesothelial cells, 197, 341
Mesothelial permeability, 135
Mesothelial secretion, 215
Mesothelium, 41
Microvilli, 341
Multilamellar bodies, 341

N-acetyl-beta-D-glucominidase, 313
Nasal carriage, 61
Nitrogen, 295
Nitroprusside, 75
Nutritional evaluation, 295

O set, 175
Ofloxacin, 267
Opsonic activity, 115
Opsonisation, 333
Osmotic tolerance, 197

Parathyroidectomy, 285
Pentoxifylline, 131
Peptidoglycan, 69
Peritoneal cells, 115
Peritoneal clearance, 75, 281
Peritoneal defences, 115
Peritoneal dialysis solutions, 325
Peritoneal function, 329
Peritoneal microcirculation, 75
Peritoneal morpholysis, 41
Peritoneal permeability, 329
Peritoneal transport, 75
Peritoneal ultrafiltration, 211
Peritoneum in vitro, 303
Peritoneum, 47, 215, 341
Peritonitis therapy, 267
Peritonitis treatment, 247
Peritonitis, 47, 57, 61, 65, 69, 73, 103, 127, 159, 165, 169, 175, 179, 191, 257, 273, 329
Permeability, 69
Peroxidase, 313
Pharmacokinetic evaluation, 267
Pharmacokinetics, 51, 57, 95
Phosphatidylcholine, 203, 207, 211
Phospholipid, 47
Pneumoperitoneum, 307
Pyrazinamide, 303

Recombinant human growth hormone (rhGH), 91
Rehabilitation, 121
Renal osteodystrophy, 277

Sodium hypochlorite, 175
Splenic abscess, 73
Staphylococcal exotoxins, 197
Staphylococcus aureus, 61
Staphylococcus epidermidis, 333
Staphylococcus, 69
Sulfamethoxazole, 51
Surface-active material, 47
Therapy, 179, 207
Therapy prescription, 257
Transperitoneal passage, 303
Transport studies, 131
Trichosporon, 79
Trimethoprim, 51
Tunnel infection, 191
Type II pneumocytes, 215

Ultrafiltration failure, 203, 207
Ultrafiltration, 107
Urea kinetics, 257
Uremia, 319
Uremic toxicity, *KT/V,* 257
Uric acid, 303
Urokinase, 65

Vimentin, 341
Visceral peritoneum, 135
Vitamin D, 281
Vitamin-D-binding protein, 281

Y connector disinfectant, 159
Y set devices, 165
Y set, 175